BRAF V600E型转移性结直肠癌治疗进展
Advancements in treatment of BRAF V600E-mutant metastatic colorectal cancer
孟令桦 1潘利华 1李瑞东 1孙力军 1叶书成1
作者信息
- 1. 济宁医学院附属医院肿瘤科(山东省济宁市 272100)
- 折叠
摘要
转移性结直肠癌(metastatic colorectal cancer,mCRC)患者中约 8%～15%存在BRAF基因突变,V600E是BRAF最常见的突变形式.BRAF V600E突变型的mCRC患者预后差,初始标准化疗效果不佳,强烈治疗的效果有限,并且在初始治疗失败后,后续治疗疗效甚微,疾病进展迅速,患者总生存期短,这类患者治疗现状不容乐观.因此,应寻找对于BRAF V600E突变型mCRC患者的更为有效治疗方案.本文将详细介绍BRAF V600E突变与mCRC患者预后及疗效预测方面的相关研究及治疗进展,以期为延长患者生存期提供参考依据.
Abstract
Approximately 8%to 15%of patients with metastatic colorectal cancer(mCRC)harbor BRAF mutation,and the V600E mutation is the most common form of BRAF mutation.The prognosis of patients with metastatic colorectal cancer harboring BRAF V600E mutation is poor.Initial standard chemotherapy is often ineffective,necessitating an intensive follow-up treatment,which usually provides limited effic-acy.Consequently,the disease becomes notably difficult to treat and progresses rapidly,resulting in a decreased overall patient survival rate.This review details the research advancements in treatment of BRAF V600E-mutant metastatic colorectal cancer.
关键词
转移性结直肠癌/BRAF/V600E/一线治疗/分子靶向治疗/免疫治疗Key words
metastatic colorectal cancer(mCRC)/BRAF V600E/first-line treatment/molecular targeted therapy/immunotherapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据